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Abstract: Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with 
moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β2 ago-
nist bronchodilators. This review considers the mechanism of action, pharmacokinetics, efficacy, safety and place in management of 
omalizumab in asthma and focuses particularly on key articles published over the last three years. Omalizumab reduces IgE mediated 
airway inflammation and its effect on airway remodeling is under investigation. Recent long-term clinical trials confirm the benefits of 
omalizumab in reducing exacerbations and symptoms in adults and in children with moderate to severe allergic asthma. No clinical or 
immunological factor consistently predicts a good therapeutic response to omalizumab in allergic asthma. In responders, the duration 
of treatment is unclear. The main adverse effect of omalizumab is anaphylaxis, although this occurs infrequently. Preliminary data from 
a five-year safety study has raised concerns about increased cardiovascular events and a final report is awaited. Clinical trials are in 
progress to determine whether omalizumab has efficacy in the treatment of non-allergic asthma.
Keywords: IgE, severe asthma, allergic asthma, omalizumabThomson and Chaudhuri
28  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2012:6
Introduction
Over 300 million individuals worldwide have asthma1 
of whom the majority have mild or moderate disease 
that  can  be  controlled  by  inhaled  corticosteroids, 
either  alone  or  in  combination  with  inhaled  long-
acting  β2  agonist  bronchodilators.1–3  Nevertheless 
a considerable proportion of patients with asthma,4 
particularly those with severe disease5 have poorly 
controlled  symptoms  and  are  at  increased  risk 
of  exacerbations.  In  some  patients  inadequately 
controlled  asthma  is  due  to  poor  adherence  with 
treatment,  untreated  co-morbidities,  dysfunctional 
breathing  or  psychological  problems.6,7  For  others, 
there  is  a  need  for  additional  or  new  therapies.8 
Severe asthma occurs in 5% to 10% of the asthmatic 
population  and  in  this  group  it  is  estimated  that 
over  50%  have  allergic  IgE-mediated  asthma.9 
Omalizumab, a recombinant humanized monoclonal 
antibody  that  binds  circulating  IgE  antibody,  is  a 
treatment  option  for  moderate  to  severe  allergic 
asthma in patients whose asthma is not well controlled 
with inhaled corticosteroids and inhaled long-acting 
β2 agonist bronchodilators.1–3 This review considers 
the mechanism of action, pharmacokinetics, efficacy, 
safety  and  place  in  management  of  omalizumab 
in  asthma  and  focuses  particularly  on  key  articles 
published over the last three years.
Mechanism of Action
Immunoglobulin E (IgE) is considered to play a key 
role  in  the  pathogenesis  of  asthma10  and  the  level 
of circulating IgE to common inhalant allergens is 
a strong risk factor for emergency admissions with 
asthma.11 Allergen specific IgE binds to high affinity 
receptors (FCεRI) on mast cells and basophils to induce 
an  allergic  reaction  through  the  release  of  a  wide 
range of inflammatory mediators such as histamine, 
tryptase and arachidonic acid metabolites.12,13 High 
affinity receptors are also expressed on other inflam-
matory cells including dendritic cells, monocytes and 
eosinophils. Omalizumab is a recombinant human-
ized monoclonal antibody that binds to the FC   portion 
of  the  IgE  antibody.  By  forming  complexes  with 
circulating IgE antibody it reduces the levels of free 
IgE and prevents the binding of IgE to high-affinity 
IgE receptors on mast cells and basophils and the sub-
sequent release of inflammatory mediators induced 
by allergen exposure14 (Fig. 1). Omalizumab cannot 
however,  bind  to  IgE  that  has  already  attached  to 
FCεRI receptors. Omalizumab treatment also down-
regulates the expression of FCεRI receptors on mast 
cells and basophils.15
There  is  considerable  interest  in  determining 
the  effects  of  omalizumab  treatment  on  chronic 
airway inflammation and remodeling in asthma.16–19 
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Figure 1. Mechanisms of action of omalizumab in allergic asthma.
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Immunol,14 copyright 2008.
Abbreviation: Fc RI, high-affinity IgE receptor.Omalizumab in the management of asthma
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A placebo controlled study of 16 weeks treatment 
with omalizumab in forty-five patients with mild to 
moderate persistent asthma with sputum eosinophilia 
of 2% or more found that active treatment resulted 
in  a  reduction  of  bronchial  biopsy  IgE+  cells  in 
the  airway  mucosa,  tissue  eosinophil  numbers 
and  CD3+,  CD4+,  and  CD8+  T  lymphocytes.16 
Omalizumab treatment was not associated however, 
with improvement in airway hyperresponsiveness to 
methacholine. In addition to reducing the early and 
late bronchoconstrictor response to inhaled allergen, 
omalizumab reduces induced sputum eosinophils and 
bronchial biopsy eosinophil numbers and IgE-bearing 
cells, but does not attenuate airway responsiveness 
to methacholine post-allergen challenge.17 A pooled 
analysis  of  data  from  five  randomized  controlled 
studies  in  2236  patients  with  moderate  to  severe 
persistent  allergic  asthma  receiving  moderate  to 
high-dose  inhaled  corticosteroids  found  a  pattern 
of  improved  clinical  outcomes,  associated  with 
decreased  peripheral  blood  eosinophils  and  worse 
clinical  outcomes  associated  with  increased 
peripheral  blood  eosinophils,  in  keeping  with  the 
efficacy of omalizumab being due, at least in part, 
with an inhibitory effect on eosinophils.20 Treatment 
of  allergic  subjects  with  omalizumab  also  reduces 
the release of Th2 cytokines from peripheral blood 
basophils.13 Taken together these studies suggest that 
treatment  with  omalizumab  reduces  eosinophilic 
airway inflammation and IgE-bearing cells, but does 
alter  airway  responsiveness.  Possible  mechanisms 
for  the  reduction  in  eosinophil  numbers,  although 
not established,21 could be explained by a reduction 
in high affinity IgE receptor numbers on dendritic 
cells causing less antigen presentation to T cells, by 
decreased release of eosinophilic chemotactic factors 
from mast cells and basophils and by the induction 
of  eosinophil  apoptosis.22  In  addition,  omalizumab 
blocks low affinity IgE receptors on epithelial cells 
and airway smooth muscle, which may decrease the 
release of eosinophil chemokines such as eotaxin.21
There  is  limited  information  on  the  effects  of 
omalizumab  on  airway  remodeling.19  Prevention 
of  degranulation  of  allergen  bound  mast  cells  by 
omalizumab prevents the release of pro-inflammatory 
cytokines, including IL-4, IL-13 and IL-5 that are 
associated  with  airway  remodeling.  The  exhaled 
breath  condensate  levels  of  endothelin-1,  a  pro-
inflammatory mediator also implicated in asthmatic 
airway inflammation and remodeling23 are reduced 
following  omalizumab,  suggesting  a  potential 
mechanism  by  which  this  therapy  could  reduce 
structural changes to the airways.24 A 16 week study 
of 30 patients with severe persistent asthma, which 
used  computed  tomography  (CT)  to  assess  airway 
dimensions, found that treatment with omalizumab 
compared  to  usual  care  was  associated  with  a 
reduction  in  indices  of  airway  wall  thickness.18 
Interestingly, the decrease in airway wall thickness 
was associated with improvements in lung function 
and  decrease  in  sputum  eosinophil  count. A  long-
term  randomized  controlled  trial  is  underway  in 
patients  with  moderate  to  severe  allergic  asthma 
to examine the effects of 78 weeks treatment with 
omalizumab  on  bronchial  biopsy  sub-epithelial 
eosinophils,  mast  cell  and  CD4+  T-lymphocytes 
as well as thickness of the lamina reticularis, as an 
index of airway remodeling (The EXPLORE study, 
www.clinicaltrials.gov NCT00670930). The findings 
of this study should provide insights into the effects 
of long-term treatment with omalizumab on airway 
inflammation and remodeling.
In  summary,  omalizumab  decreases  allergic 
airway  inflammation  by  reducing  the  expression  of 
high affinity IgE receptors on inflammatory cells and 
eosinophil numbers within the airways. Research is 
underway to help establish whether long-term treatment 
with omalizumab also reduces airway remodeling.
Metabolism and pharmacokinetic 
Profile
The  metabolism  and  pharmacokinetic  profile  of 
omalizumab has been previously reviewed in detail.25 
After  a  single  subcutaneous  dose  in  adult  and 
adolescents  with  asthma,  omalizumab  is  absorbed 
slowly  over  several  days,  reaching  peak  serum 
concentrations  after  an  average  of  seven  to  eight 
days.25,26 The  pharmacokinetics  of  omalizumab  are 
linear at doses above 0.5 mg per kg. Measurements 
of  omalizumab  serum  concentrations  reflect  the 
combination  of  free  omalizumab  and  that  bound 
to  IgE.  Serum  free  IgE  levels  reduce  in  a  dose-
dependent  manner  within  one  hour  of  the  first 
dose  of  omalizumab  and  levels  are  maintained 
between doses, whereas concentrations of total IgE 
(ie,  the  sum  of  free  and  omalizumab  bound  IgE) Thomson and Chaudhuri
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are increased. Information about drug distribution is 
limited to reports from intravenous administration of 
radiolabeled omalizumab in cynomolgus monkeys.27 
These studies suggest that most of the drug remains 
in the central intravascular compartment, with little 
accumulation in tissues. Elimination of omalizumab 
appears to involve IgG clearance processes as well as 
clearance via specific binding and complex formation 
with its target ligand, IgE. Liver elimination of IgG 
includes degradation in the reticulo-endothelial system 
and endothelial cells. Intact IgG is also excreted in 
bile. In patients with asthma, the omalizumab serum 
elimination half-life averages 26 days, with apparent 
clearance rates averaging 2.4 ± 1.1 mL per kg per day. 
In addition, doubling of body weight approximately 
doubles clearance rates. The half-life of omalizumab 
is  variable,  with  values  ranging  from  one  to 
four weeks.25 After discontinuation of omalizumab, 
free and total IgE concentrations approach baseline 
slowly.  In  a  dose-ranging  study  involving  patients 
with ragweed seasonal allergic rhinitis, average free 
IgE concentrations returned to baseline within eight 
weeks of the last omalizumab infusion.28 Total IgE 
concentrations  generally  take  longer  to  approach 
baseline  after  stopping  therapy.28,29  One  year  after 
discontinuation  of  omalizumab  dosing,  circulating 
IgE  levels  return  to  baseline  pre-treatment  levels 
with no observed rebound.26 Analyses of population 
pharmacokinetics  of  omazulamab  suggest  that  no 
dose adjustments are necessary for the age range 6 to 
76 years, race, ethnicity, gender or Body Mass Index. 
There are no pharmacokinetic or pharmacodynamic 
data in patients with renal or hepatic impairment.26
Efficacy
The main evidence for the efficacy of omalizumab 
in the treatment of patients with allergic asthma is 
summarized in two systematic reviews.30,31 A Cochrane 
review  published  in  2006  of  14  randomized  con-
trolled trials in 3143 children and adults with mild 
to severe allergic asthma found that treatment with 
omalizumab reduced asthma exacerbations (OR 0.52, 
95% CI, 0.41 to 0.65) and increased the proportion of 
patients who were able to reduce or withdraw inhaled 
corticosteroids.30  A systematic review published in 2011 
of 8 randomized controlled trials in 3,429 children and 
adults with moderate to severe allergic asthma taking 
inhaled corticosteroids, including two trials published 
after 2006,32,33 concluded that omalizumab treatment 
resulted in a higher proportion of subjects stepping-
down and stopping inhaled corticosteroids (relative 
risk [RR] = 1.80; 95% CI, 1.42–2.28) and reduced 
the risk of asthma exacerbations (RR = 0.57; 95% CI, 
0.48–0.66).31 Data from the systematic review pub-
lished in 201131 suggested that the number needed to 
treat for benefit (NTTB) in reducing the rate of exacer-
bations was 10. A post-hoc analysis suggested that the 
beneficial effects of omalizumab were not dependent 
on the age, duration of treatment, or disease severity.31 
A study included in the systematic review that pro-
vided evidence for the efficacy of omalizumab in chil-
dren was a 52 week randomized placebo-controlled 
trial in 627 children aged 6 to ,12 years with peren-
nial allergen asthma and a history of exacerbations 
and poor symptom treatment with   medium-dose or 
high-dose  inhaled  corticosteroids  with  or  without 
other controller medications.32 Omalizumab treatment 
reduced asthma exacerbations by 31% compared to 
placebo during the first 24-weeks of the study, when 
the inhaled corticosteroid dose remained stable, and 
by 43% over a period of 52 weeks, which included 
a  28-week  adjustable-corticosteroid  phase.32  In  this 
study the secondary outcomes including symptoms, 
reliever bronchodilator use and reduction in inhaled 
corticosteroid dose were not significantly improved 
by omalizumab treatment.
Recent publications have provided important new 
information on the use of omalizumab as an add-on 
treatment  to  high  dose  inhaled  corticosteroids  and 
inhaled  long-acting  β2  agonist  bronchodilators  in 
severe allergic asthma34,35 and in children and young 
adults with allergic asthma36 (Table 1). A randomized 
controlled trial in 850 patients who had inadequately 
controlled  asthma  despite  treatment  with  high  dose 
inhaled  corticosteroids  ($500  mcg  of  fluticasone 
inhaler twice daily or equivalent) and inhaled long-
acting  β2  agonist  bronchodilators,  with  or  without 
other controllers assessed the benefits of the addition of 
omalizumab over a 48 week period.34 At the end of the 
treatment period omalizumab produced a 25% relative 
reduction  in  the  rate  of  asthma  exacerbations  (0.66 
omalizumab vs. 0.88 placebo per patient) (Table 1). 
This study demonstrates clinical benefits obtained from 
the addition of omalizumab to patients with poorly 
controlled  severe  allergic  asthma  despite  treatment 
with  high  dose  inhaled  corticosteroids  and  inhaled Omalizumab in the management of asthma
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long-acting β2 agonist bronchodilators, although the 
magnitude of benefit is relatively small. Interestingly 
there was a large placebo effect observed in the control 
group,  a  finding  which  has  been  noted  in  previous 
studies  with  omalizumab.30,35 At baseline, seventeen 
percent of participants were receiving either chronic 
oral corticosteroids or an oral corticosteroid course at 
least 4 times per year, and in this sub-group there was 
no clinical benefit although it should be noted that the 
study was not powered to detect a treatment effect.
A  recent  double-blind,  placebo-controlled 
study in 271 patients aged 12 years or older with 
physician diagnosed persistent allergic asthma com-
pared the efficacy of omalizumab with placebo over 
24 weeks period.35 There was no significant differ-
ence with omalizumab treatment in the change from 
baseline in the primary outcome measure, the Asthma 
Control  Test  (ACT)  total  score,  compared  with 
placebo. In a subgroup of patients with very poorly 
controlled asthma (ACT # 15) at baseline however, 
significant  benefits  were  observed  for  omalizumab 
compared with placebo for change in ACT score. The 
results of this study suggest that omalizumab has little 
impact on ACT scores, except in those patients with 
very poorly controlled asthma.35
A  randomized  controlled  trial  in  419  inner-city 
children, adolescents, and young adults with persistent 
allergic asthma examined the benefits of the addition 
Table 1. Summary of recent key randomized placebo-controlled clinical trials of omalizumab as an add-on treatment in 
children and young adults with allergic asthma.
Author participants Duration Main outcomes
Hanania et al, 
Ann Int Med34
850 patients aged 12 to 75 years who 
had inadequately controlled asthma  
despite treatment with high dose  
inhaled corticosteroids ($500 mcg  
of fluticasone inhaler twice daily or  
equivalent) and inhaled long-acting  
β2 agonist bronchodilators, with or  
without other controllers
48 weeks At the end of the treatment period omalizumab 
produced a 25% relative reduction in the primary 
outcome, rate of asthma exacerbations  
(0.66 omalizumab vs. 0.88 placebo per patient, 
P = 0.006), as well as producing improvements  
in several secondary efficacy end-points including 
an non-clinically significant increase in the mean 
asthma quality of life questionnaire (AQLQ) 
score (0.29 points) and a decrease in mean daily 
number of puffs of albuterol (-0.27 puffs per day) 
and in mean total asthma symptom score  
(-0.26) compared with placebo.
Bardelas et al,  
J Asthma35
271 patients aged 12 years or older  
with physician diagnosed persistent 
allergic asthma
24 weeks There was no significant difference with 
omalizumab treatment in the change from 
baseline in the primary outcome, the Asthma 
Control Test (ACT) total score, compared  
with placebo. 
In a subgroup of patients with very poorly 
controlled asthma (ACT # 15) at baseline 
however, significant benefits were observed for 
omalizumab compared with placebo for change  
in ACT score.
Busse et al,  
N eng J Med36
419 inner-city children,  
adolescents, and young adults with  
persistent allergic asthma.  
Almost three quarters of participants  
had moderate or severe asthma
60 weeks At the end of the treatment period omalizumab, 
compared to placebo, produced a 25% relative 
reduction in the primary outcome, number 
of days with asthma symptoms, from 1.96 to 
1.48 days per 2 week interval (P , 0.001) as 
well as producing a reduction in the proportion 
of subjects who had one or more exacerbations 
from 48.8% in the placebo group to 30.3% in the 
omalizumab group and in the hospital admissions 
because of asthma from 6.3% to 1.5%.  
In addition, the omalizumab treatment group 
reduced the use of inhaled corticosteroids and 
inhaled long-acting β2 agonist bronchodilators.
Abbreviation: RCT, Randomized placebo controlled trial.Thomson and Chaudhuri
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of omalizumab to guideline based treatment over a 
60 week period.36 Almost three quarters of participants 
had moderate or severe asthma. At the end of the 
treatment period omalizumab, compared to placebo, 
produced a 25% relative reduction in the number of 
days with asthma symptoms (Table 1, Fig. 2) as well 
as producing a reduction in the proportion of subjects 
who had one or more exacerbations from 48.8% in 
the placebo group to 30.3% in the omalizumab group 
and in the hospital admissions because of asthma from 
6.3% to 1.5%. A post hoc analysis revealed a marked 
reduction in seasonal exacerbation with omalizumab. 
In addition to confirming the clinical benefits from 
omalizumab treatment in children and young adults 
with allergic asthma, this study provides evidence for 
the importance of sensitization to cockroach allergen 
and house dust mites in an inner-city US population 
of individuals with allergic asthma.
Several  observational  studies  have  reported  on 
‘real  life’  experience  with  omalizumab  in  treating 
patients with allergic asthma in France,37 Germany,38 
Belgium,39 United Kingdom,40 Italy,41 South-Eastern 
Mediterranean  centers,42  Israel43  and  Spain.44  The 
most recent and largest study reported on the efficacy, 
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Figure 2. Omalizumab in inner-city children, adolescents, and young adults with persistent allergic asthma. 
note: The figure shows the number of days with symptoms (per 2-week interval), frequency of exacerbations, and dose of inhaled glucocorticoid over the 
duration of the study. 
Reproduced from Busse et al with permission.36 Copyright (c) Massachusetts Medical Society.Omalizumab in the management of asthma
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tolerability  and  IgE  entry  criteria  of  omalizumab 
treatment of 266 patients with uncontrolled severe 
asthma receiving high dose inhaled corticosteroid and 
inhaled long-acting β2 agonist bronchodilators.44 The 
main efficacy outcome of exacerbations, ACT score 
and global evaluation of treatment effectiveness all 
improved at 4 months and at 2 years including patients 
with “off label” IgE levels. Omalizumab treatment 
was stopped in a minority of patients because of a 
lack  of  efficacy.  The  study  provides  data  from  a 
  longer follow-up period (over 2 years) than previous 
observational studies. Taken together, the results of 
these studies suggest that omalizumab is an effective 
treatment for patients with poorly controlled allergic 
asthma  and  that  efficacy  outcomes  in  a  ‘real  life’ 
setting are similar to those reported in clinical trials.
Omalizumab  reduces  the  severity  of  the  acute 
bronchoconstrictor  response  to  environmental 
exposure to cat allergen.45 A randomized controlled 
trial undertaken in 69 patients who gave a history of 
cat  allergen–induced  asthma  examined  the  effects 
of 16 weeks treatment with omalizumab or placebo 
on  controlled  exposure  to  cat  allergen.45 After  cat 
allergen  exposure  the  area  under  the  curve  for 
percentage  decrease  in  FEV1  was  15.2%  per  hour 
for  omalizumab-treated  patients  compared  with 
27.3% per hour for patients who received placebo. 
Symptoms caused by exposure to cat allergens were 
also reduced by treatment with omalizumab. These 
findings suggest that omalizumab may have a role in 
the treatment of patients with cat allergen–induced 
asthma when avoidance measures and/or drug therapy 
are not effective in controlling the severity of acute 
asthma symptoms during environmental exposure to 
cat allergen. A large proportion of patients with severe 
allergic asthma also have chronic allergic rhinitis and 
in this group of patients, omalizumab treatment over 
a 26 week period improves both asthma and rhinitis 
quality of life questionnaire scores.46
There is interest in whether omalizumab may be of 
value in the treatment of other forms of asthma includ-
ing non-allergic asthma. A case report of a patient with 
severe persistent asthma, who had elevated total IgE 
levels and negative specific IgE and skin-prick test 
results, noted a good clinical response to an open trial 
of omalizumab treatment, which was followed by a 
deterioration after its withdrawal.47 Several random-
ized controlled clinical trials are underway to assess 
the clinical and immunological effects of omalizumab 
in severe non-atopic asthma. The primary outcomes in 
one study are lung function and exacerbations (www.
clinicaltrials.gov  NCT01113437),  and  in  another 
study  the  expression  of  FcεRI  receptors  on  blood 
basophils  and  dendritic  cells  (www.clinicaltrials.
gov NCT01007149). Hopefully the results of these 
clinical trials will help clarify the role of omalizumab 
therapy in the treatment of non-atopic asthma. A study 
to evaluate the effect of omalizumab on improving 
the tolerability of specific allergen immunotherapy in 
248 patients with at least moderate persistent allergic 
asthma, with the aim of reducing systemic allergic 
reactions, reported that the number of participants with 
systemic allergic reactions to specific immunother-
apy was numerically lower after 26 weeks treatment 
with  omalizumab  (13.5%)  compared  to  placebo 
(26.2%).48 A observational study of 18 patients with 
aspergillus-associated airway diseases recruited from 
11 centers in Spain reported on the clinical benefits 
of omalizumab treatment for a median follow-up of 
36 weeks.49 The treatment was discontinued in five 
patients due to a lack of efficacy and one because of a 
positive pregnancy test. In the remaining 12 patients 
there were improvements in symptoms, exacerbations 
and lung function. Based on these preliminary find-
ings in patients with aspergillus sensitization associ-
ated asthma, prospective placebo controlled trials are 
indicated.
In summary, recent long-term clinical trials confirm 
the benefits of omalizumab in reducing exacerbations 
and symptoms in adults and in children with moderate 
to severe allergic asthma.
Safety
There is increasing data on the safety of the short and 
long term use of omalizumab, as numbers of patients 
in clinical trials and clinical use has expanded. An 
analysis of over 7,500 patients recruited to clinical 
trials of omalizumab and of 57,300 patients included 
in  post-marketing  safety  follow-up  monitoring 
revealed a generally favorable safety profile.50 The 
major  adverse  effect  associated  with  the  use  of 
omalizumab is anaphylaxis. In addition concerns have 
been raised about an increase in malignancy rates and 
cardiovascular and cerebrovascular events (Table 2).
The incidence of anaphylaxis reported in clinical 
trials is 0.14% in omalizumab treated patients and Thomson and Chaudhuri
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0.07% in control patients in clinical trials and 0.2% 
with  omalizumab  treatment  from  post-marketing 
data.50 Nearly 60% of anaphylactic episodes devel-
oped in the first two hours after the administration of 
omalizumab; 39% occurred after the first dose, 19% 
following the second and 10% with the third dose 
and a previous history of anaphylaxis was reported 
in 24% of subjects.51 Recommendations of the US 
Omalizumab  Joint  Task  Force  guideline  published 
in 2007 include informed consent, patient education 
about anaphylaxis symptoms, supply of an epineph-
rine auto-injector and a waiting period of two hours 
following the first 3 injections and 30 minutes for sub-
sequent injections.52 According to the European Med-
icines Agency (EMA) licence, medications for the 
treatment of anaphylactic reactions should be avail-
able in areas where omalizumab is administered and 
patients should be informed of the potential for such 
reactions and the need for prompt medical attention 
should reactions occur.53
The  overall  incidence  of  observed  malignancy 
associated  with  omalizumab  use  is  rare  and 
comparable  to  that  in  the  general  population.26,51 
In  clinical  trials  in  adults  and  adolescents,  there 
was a numerical imbalance in cancers arising in the 
omalizumab group (0.5%) compared with the control 
group (0.18%).26 A causal relationship was considered 
unlikely given the diversity in the type of cancers, the 
relatively short duration of exposure and the clinical 
features of the individual cases.26 There were no cases 
of malignancy with omalizumab in the clinical trials 
in children 6 to ,12 years of age; there was a single 
case of malignancy in the control group.26 In a recent 
pooled  analysis  from  67  clinical  trials  including 
11,459 patients of whom 7789 received omalizumab, 
25  malignancies  [14  and  11  in  omalizumab  and 
placebo treated patients respectively] were identified. 
Incidence rates per 1,000 patient-years of observation 
time  for  omalizumab-  and  placebo-treated  patients 
were  4.14  (95%  CI,  2.26–6.94)  and  4.45  (95% 
CI,  2.22–7.94),  respectively.  No  association  was 
observed  between  omalizumab  treatment  and  risk 
of malignancy suggesting that a causal relationship 
between omalizumab therapy and malignancy is not 
likely.54
Recently  concerns  about  the  cardiovascular 
and  cerebrovascular  safety  of  omalizumab  have 
been  raised  by  the  United  States  Food  and  Drug 
  Administration  (FDA),  based  on  preliminary  data 
from a five year epidemiological study designed to 
evaluate the clinical effectiveness and long-term safety 
in patients with moderate to severe asthma (EXELS).55 
Detailed results from this study are expected later this 
year. The numerical imbalance of arterial thrombotic 
events (ATEs) observed in clinical trials and in the 
EXCELS cohort, included stroke, transient ischemic 
attack,  myocardial  infarction,  unstable  angina,  and 
cardiovascular death (including death from unknown 
cause). The rate of ATE in patients in the controlled 
clinical trials was 6.29 for omalizumab treated patients 
and 3.42 for control patients. In a Cox proportional 
hazards model, omalizumab was not associated with 
ATE risk (hazard ratio 1.86; 95% confidence interval 
0.73–4.72). In the observational study, the rate of ATE 
was 5.59 for omalizumab treated patients and 3.71 for 
control patients. In a multivariate analysis controlling 
Table 2. Adverse effects of omalizumab.†
common [,1/10]
•  Pyrexia*
• Abdominal pain upper*
•  Headache*
•    Injection site reactions such as swelling, erythema, 
pain, pruritus
Uncommon [.1/1000 to ,1/100]
•  Pharyngitis
•  Syncope, paraesthesia, somnolence, dizziness
•  Postural hypotension, flushing
• Allergic bronchospasm, coughing
•  Dyspeptic signs and symptoms, diarrhoea, nausea
•  Photosensitivity, urticaria, rash, pruritus
•    Influenza-like illness, swelling arms, weight increase, 
fatigue
Rare [$1/10,000 to ,1/1000]
•  Parasitic infection
• Anaphylactic reaction, other serious allergic conditions
•  Laryngoedema
• Angioedema
Frequency not known [cannot be estimated from 
available data]
•  Idiopathic severe thrombocytopenia
•    Serum sickness, may include fever and 
lymphadenopathy
•   Allergic granulomatous vasculitis (ie, Churg-Strauss 
syndrome)
• Alopecia
• Arthralgia, myalgia, joint swelling
notes:  †Adapted  from  Summary  of  Product  Characteristics;26  *very 
common in children 6 to ,12 years of age [$1/10].Omalizumab in the management of asthma
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for baseline cardiovascular risk factors, omalizumab 
was not associated with ATE risk (hazard ratio 1.11; 
95% confidence interval 0.70–1.76).26
An  exploratory  study  in  Brazil  studied  whether 
anti-IgE treatment of patient with allergic asthma and/
or rhinitis would increase the risk of infections with 
intestinal  helminths.56  Following  a  course  of  anti-
helminthic treatment, all subjects received omalizumab 
or placebo for 52 weeks. Half the omalizumab treated 
subjects experienced at least one intestinal helminth 
infection  compared  with  41%  of  placebo  subjects, 
suggesting  a  slight  increase  in  the  incidence  of 
helminth infection, although the difference was non-
significant.  The  current  drug  summary  of  product 
characteristics advises caution in patients at high risk 
of helminth infection, in particular when travelling 
to areas where these infections are endemic, and if 
patients do not respond to recommended anti-helminth 
treatment, discontinuation of omalizumab should be 
considered.26
Adverse  events  do  not  appear  to  occur  more 
frequently in older people. An observational study in 
a ‘real life’ population of 280 people reported adverse 
events in 35.5% of patients 50 years or older and, at 
a similar frequency, in 32.1% of younger patients.57 
Omalizumab  is  designated  a  Pregnancy  Category 
B  drug  and  animal  studies  have  not  demonstrated 
a  risk  to  the  foetus.51  The  EXPECT  registry,  an 
observational  registry  following  women  who  have 
received  omalizumab  during  pregnancy  or  prior 
to  conception  will  provide  further  information. 
In the 27 cases of pregnancy occurring in patients 
receiving omalizumab in clinical trials, no significant 
issues were observed in abortion rates or abnormal 
deliveries.51 The current opinion is that due to lack of 
adequate data, omalizumab should not be used during 
pregnancy unless clearly necessary and women should 
not breast feed during therapy.26
In summary, the main adverse effect of omalizumab 
is  anaphylaxis,  although  this  occurs  infrequently. 
  Preliminary data from a five-year safety study has 
raised concerns about increased cardiovascular events 
and a final report is awaited.
Place in Therapy
In 2003, omalizumab was approved by the FDA for 
the treatment of adults and adolescents aged 12 years 
and above with moderate to severe persistent allergic 
asthma whose symptoms are poorly controlled with 
inhaled  corticosteroids.58  A  Black  Boxed  adverse 
effects warning issued in 2007 advising of the risk of 
the delayed development of anaphylaxis after admin-
istration of omalizumab and a further warning issued 
in 2009 notified of interim safety findings from the 
EXCELS study of a possible increase in the number 
of cardiovascular and cerebrovascular adverse events 
in treated patients. The European Medicines Agency 
(EMA) licensed omalizumab in 2005 for the treatment 
of severe allergic asthma in patients aged 12 years 
or older in whom symptoms are poorly controlled, 
including a history of multiple exacerbations, despite 
inhaled high dose corticosteroids and inhaled long-
acting β2 agonist bronchodilators and in whom the 
FEV1 , 80%. In 2009 the licence was extended to 
include children aged 6 to ,12 years as an add-on 
treatment for poorly controlled asthma in patients with 
severe persistent allergic asthma.59 In addition to the 
US and Europe, omalizumab is licensed for treating 
patients with moderate to severe allergic asthma in a 
large number of other countries worldwide including 
Australia, Canada and Brazil.
current Guidelines
The US National Asthma Education and Prevention 
Expert  Panel  Report  3  (EPR-3)  guideline,3  the 
international  Global  Initiative  for Asthma  (GINA) 
guideline1 and the British guideline on the management 
of asthma2 have similar recommendations on the man-
agement of chronic asthma, with step-wise treatment 
aimed at controlling symptoms. Steps 4 to 6 of the 
EPR-3 guideline and Steps 4 and 5 of the GINA and 
British guidelines are the stage at which asthma is 
considered severe. Anti-IgE therapy is recommended 
by the EPR-3 guidelines at steps 5 and 63 and the 
GINA1 and British2 guidelines for patients at step 5.
Indications
For the purpose of using omalizumab the term allergic 
is defined as a positive skin test or in vitro reactivity 
to a perennial aeroallergen and in addition the serum 
total IgE levels should be in the range 30 to 700 IU/
mL in the US. In Europe the serum total IgE ranges 
are $30 to #1500 IU/mL in adults and children .12 
years and ,1300 IU/mL for children over 6 years. 
The dose (mg) of omalizumab and dose frequency is 
based on the serum total IgE level (IU/mL) and the Thomson and Chaudhuri
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patient’s body weight (kg). Based on this calculation, 
omalizumab is given at a dose of 150 to 375 mg by 
subcutaneous injection every 2 or 4 weeks. The main 
contraindication is a past history of a severe hyper-
sensitivity reaction to omalizumab. There is limited 
data on the efficacy of omalizumab in active ciga-
rette smokers with allergic asthma, as this group is 
usually excluded from clinical trials of omalizumab, 
although it is likely that the efficacy will be similar to 
that reported in non-smokers with allergic asthma.60
Assessment of Therapeutic Response
Several  studies  have  tried  to  identify  clinical  or 
immunological factors that predict a good therapeutic 
response to omalizumab.61–63 Based on a pooled analysis 
from seven randomized controlled omalizumab trials, 
Bousquet and colleagues62 concluded that treatment 
benefits were not related to baseline total IgE levels. 
However,  in  the  INvestigatioN  of  Omalizumab 
in  seVere  Asthma  TrEatment  (INNOVATE)  study 
undertaken  in  patients  with  severe  allergic  asthma 
and included in the pooled analysis, baseline total 
IgE was the only predictor of efficacy64 and levels 
of specific IgE for individual allergens were of no 
additional benefit in predicting a positive response.63 
In  inner-city  US  children,  adolescents,  and  young 
adults  with  persistent  allergic  asthma  the  presence 
of sensitization and exposure to cockroach allergen 
predicted  a  very  good  response  to  omalizumab.36 
It  has  been  reported  that  patients  receiving  long-
term oral corticosteroids or frequent courses of oral 
corticosteroids  respond  poorly  to  omalizumab,34 
although there is some limited evidence to support an 
oral corticosteroid sparing effect of omalizumab.65 An 
open-label study of 82 patients with severe allergic 
asthma, found the addition of omalizumab therapy 
resulted  in  lower  mean  (SD)  percent  maintenance 
oral corticosteroid use after 32 weeks of treatment 
(-45.0%)  compared  with  that  in  23  patients  who 
received usual care (18.3%).65
It is recommended that a decision is made whether 
to continue long-term treatment based on assessment 
of  response  made  after  16  weeks  of  treatment,61 
although a recent study reported that the maximum 
effect  of  omalizumab  occurred  within  4  weeks  of 
starting treatment.36 In several studies of omalizumab, 
the  physician’s  overall  assessment  at  16  weeks 
following a course of treatment was the best predictor 
of a continuing beneficial response.62,66 Nevertheless 
the  combination  of  objective  measurements  of 
efficacy,  such  as ACQ,  as  well  as  the  physicians’ 
and  patients’  overall  assessment  are  often  used  to 
assess response, although these tools have not been 
validated. Cardiopulmonary exercise testing has been 
advocated  as  an  additional  method  to  assess  and 
confirm a clinical response to omalizumab in patients 
with  severe  asthma  although  to  date  the  utility  of 
exercise testing as not been investigated in a large 
number of patients.67
Duration of treatment
Once  a  patient  is  considered  to  respond  to  omali-
zumab, treatment is then continued often for several 
years. It remains uncertain when treatment can be dis-
continued or whether prolonged treatment is required. 
Certainly a dose reduction at 6 months, in patients 
who were responders at 16 weeks, is associated with 
a recurrence of symptoms.68 A small study of patients 
with  severe  cat  allergen-induced  asthma  reported 
good symptom control and reduced basophil aller-
gen sensitivity three years following completion of 
six  years  treatment  with  omalizumab,69  suggesting 
that treatment may not need to be indefinite, although 
whether this conclusion applies to patients who do 
not have cat allergen-induced asthma is not known.
special populations
There  is  no  clear  indication  on  the  safety  of 
omalizumab in pregnancy, although animal studies in 
monkeys have not reported adverse effects. Physicians 
need to assess the risk and benefits of treatment with 
omalizumab during pregnancy on an individual basis. 
In the US, a pregnancy exposure register has been 
established  to  help  provide  observational  data  on 
the use of omalizumab. There is limited data in the 
efficacy and safety of omalizumab in older patients 
over 65 years. Since omalizumab prevents seasonal 
peaks in asthma exacerbations it has been suggested 
that a seasonal course of treatment in individuals at 
high risk should be studied, as this approach would 
reduce  the  cost  of  treatment.36 A  recommendation 
for the use of omalizumab in the treatment of non-
allergic asthma and other sub-groups of asthma will be 
informed by the results of clinical trials underway.
In  summary,  omalizumab  is  a  treatment  option 
for patients with moderate to severe allergic asthma Omalizumab in the management of asthma
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whose  asthma  is  poorly  controlled  with  inhaled 
corticosteroids  and  inhaled  long-acting  β2  agonist 
bronchodilators. No clinical or immunological fac-
tors consistently predict a good therapeutic response 
to omalizumab in allergic asthma. In responders, the 
duration of treatment is unclear. Clinical trials are 
underway to determine whether omalizumab has effi-
cacy in the treatment of non-allergic asthma.
cost
An assessment of the cost effectiveness of omalizumab 
in  adults  and  adolescents  with    moderate-to-severe 
allergic asthma concluded that treatment should be 
reserved for patients with poorly controlled symp-
toms despite maximal therapy, given the high cost 
and modest efficacy of omalizumab.70 A cost effec-
tiveness analysis relevant to the US population sug-
gests that adding omalizumab to usual care improves 
quality-adjusted survival (QALYs), but at an increase 
in direct medical costs; the incremental cost-effec-
tiveness ratio (ICER) of omalizumab compared to 
usual  care  was  $172  300/QALY  in  responders.71 
Similar conclusions were reported from a cost effec-
tiveness analysis based on a ‘real-life’ 1-year ran-
domized open-label study using costs in   Canada.72 
Uncertainty has been expressed over the excess mor-
tality rates applied to severe exacerbations used in 
models in the UK to assess the cost-  effectiveness 
of omalizumab.73 Due to the high cost of treatment, 
individual countries have issued specific criteria for 
use of omalizumab to maximise benefit in selected 
populations of patients. For example, in the UK, the 
National Institute of Health and Clinical Excellence 
(NICE) recommends that omalizumab should only 
be used in adult patients who give a history of two 
or  more  severe  exacerbations  of  asthma  requiring 
admission to hospital within the previous year, or 
three or more severe exacerbations within the pre-
vious year including at least one of which required 
hospital admission.74 NICE does not recommended 
omalizumab  for  the  treatment  of  severe  persistent 
allergic asthma in children aged 6–11 years based 
on a review that concluded that omalizumab in addi-
tion  to  standard  therapy  compared  with  standard 
therapy alone did not appear cost-effective in either 
the overall population or a subgroup of patients hos-
pitalised in the year prior to enrolment.75 In Scotland, 
the Scottish Medicines Consortium (SMC) restricts 
its use to patients with chronic oral corticosteroid 
dependent severe allergic asthma.76
conclusions
Omalizumab  is  a  recombinant  humanized 
monoclonal  antibody  that  binds  circulating  IgE 
antibody. It is approved in the US and Europe, as 
well as many other countries, for the treatment of 
adults  and  adolescents  aged  12  years  and  above 
with moderate to severe persistent allergic asthma, 
whose symptoms are poorly controlled with inhaled 
corticosteroids,  plus  in  Europe  patients  should 
also  be  receiving  inhaled  long-acting  β2  agonist 
bronchodilators. In Europe, the licence also includes 
children aged 6 to ,12 years as an add-on treatment 
for  poorly  controlled  asthma  in  patients  with 
severe persistent allergic asthma. Both national and 
international  guidelines  recommend  omalizumab 
for  patients  with  severe  allergic  asthma  that  is 
not  controlled  with  other  therapies.  Omalizumab 
decreases allergic airway inflammation by reducing 
the  expression  of  high  affinity  IgE  receptors  on 
inflammatory cells and eosinophil numbers within 
the airways. Research is underway to help establish 
whether  long-term  treatment  with  omalizumab 
also reduces airway remodeling. Recent long-term 
clinical trials confirm the benefits of omalizumab in 
reducing exacerbations and symptoms in adults and 
in children with moderate to severe allergic asthma. 
No clinical or immunological factors consistently 
predict a good therapeutic response to omalizumab 
in  allergic  asthma.  In  responders,  the  duration  of 
treatment  is  unclear.  The  main  adverse  effect  of 
omalizumab  is  anaphylaxis,  although  this  occurs 
infrequently. Preliminary data from a five year safety 
study raised concerns about increased cardiovascular 
events and a final report is awaited. Clinical trials 
are in progress to determine whether omalizumab 
has efficacy in the treatment of non-allergic asthma.
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